ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1999

Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
Abstract Number: 0191

Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties
Abstract Number: 0036

Patient-specific and Disease-related Determinants for Cardiovascular Disease (CVD) Risk Stratification in the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Clinical Trial Cohort
Abstract Number: PP22

Patients Raising Awareness for Patients – A Collaborative Partnership Between Take a Pain Check Foundation and Canadian Arthritis Patient Alliance
Abstract Number: 0256

Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Different Circulating Auto-antibody Repertoires
Abstract Number: 0138

Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry
Abstract Number: 1464

Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations
Abstract Number: 1444

Patients with Lupus Pericarditis Have the Impact on the Poor Survival Outcome: A Retrospective Cohort Study
Abstract Number: 0906

Patients with Seronegative Rheumatoid Arthritis Have a Different Ultrasound-assessed Joint Disease Phenotype Than Seropositive Patients
Abstract Number: 1280

Patients with Systemic Lupus Erythematosus Perceive the Quality of Care They Receive to Be Suboptimal
Abstract Number: 2165

Patients with Systemic Sclerosis Have Impaired Forced Vital Capacity, Even in the Absence of Interstitial Lung Disease
Abstract Number: 1338

Patients’ Perspectives and Experiences of Medication Use in Osteoporosis – a Qualitative Systematic Review and Thematic Synthesis
Abstract Number: 0967

Patterns of Breastfeeding Among Women with and Without Systemic Lupus Erythematosus
Abstract Number: 1452

Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis
Abstract Number: 1933

PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].